Recent news

Archived news



Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and environmental processes has been granted with United States patent no US 10,874,735 B2.


USA_29.12
.pdf
Download PDF • 1.88MB



The National Centre for Research and Development grant TECHMATSTRATEG-III/0042/2019 (2020-2023) received by the Institute for Biotechnology and Molecular Medicine in partnership with BioVentures Institute: Biopolymer materials with chemically and genetically programmed heavy metal selectivity for new generation ultra-sensitive biosensors. Amount of funding: 4.5 mln Euro.



Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and environmental processes has been granted with European Union patent no EP 3 134 426 B1.


Patent EP 3 134 426 B1
.pdf
Download PDF • 1.91MB